# QuantalX Neuroscience

> QuantalX Neuroscience develops Delphi-MD™, an FDA De Novo-cleared, device-based
> diagnostic that directly measures how brain networks function. It integrates
> focused Transcranial Magnetic Stimulation (TMS) with high-resolution EEG to
> produce objective, quantitative brain-function data at the point of care.

Delphi-MD works in three steps. A brief, focused magnetic pulse stimulates a
selected cortical target and activates the underlying functional brain network.
High-resolution electrophysiological sensors capture the brain's direct response
over the following 300 milliseconds. Proprietary algorithms translate that
response into an objective, physician-ready readout of brain function.

The purpose is to add functional information where structural imaging alone does
not show how the brain is actually working, supporting earlier detection,
longitudinal monitoring and more informed clinical decisions.

## Core pages

- [Home](https://www.quantalx.com/): Company overview and how Delphi-MD works.
- [Technology](https://www.quantalx.com/technology): The three technological pillars behind Delphi-MD — focused high-resolution magnetic stimulation, direct brain-signal recording, and algorithmic analysis.
- [Solutions](https://www.quantalx.com/solutions): Index of clinical areas served.
- [About](https://www.quantalx.com/about): Company, mission and leadership.
- [Contact](https://www.quantalx.com/contact): Enquiries and demo requests.

## Clinical areas

- [Neurology](https://www.quantalx.com/solutions/neurology): Network-based brain function data supporting diagnosis, treatment planning and assessment of treatment response.
- [Neurosurgery](https://www.quantalx.com/solutions/neurosurgery): Objective, quantitative brain-network information that complements clinical and structural assessments in neurosurgical evaluation.
- [Brain Health](https://www.quantalx.com/solutions/brain-health): Brain function assessment as part of preventative care, including trend analysis over time.
- [Psychiatry](https://www.quantalx.com/solutions/psychiatry): Network-specific insight to support treatment selection and track change over time.
- [Clinical Research](https://www.quantalx.com/solutions/research): Standardized, reproducible TMS-EEG data for academic and clinical research and for pharmacodynamic evaluation in CNS drug development.

## For patients and families

- [Patients](https://www.quantalx.com/patients): What a Delphi-MD assessment involves, written for patients, family members and caregivers.

## Evidence

- [Peer-reviewed publications](https://www.quantalx.com/publications): Published research on Delphi-MD.
- [Clinical Publications Booklet](https://www.quantalx.com/clinical-publications): Curated collection of peer-reviewed evidence across brain health and neurological conditions, available on request.
- [Resources](https://www.quantalx.com/resources): Publications, videos, white papers and media in one hub.
- [Achievements](https://www.quantalx.com/achievements): Regulatory milestones and recognition.

## Regulatory and reimbursement

- [Coding and billing resources](https://www.quantalx.com/reimbursement): Coding, coverage and documentation reference for teams introducing Delphi-MD into an existing clinical workflow. **Coding and reimbursement support is currently available in the United States only.**
- [FDA De Novo clearance](https://www.quantalx.com/press/quantalx-receives-fda-de-novo-clearance-for-delphi-md-establishing-a-new-modality-of-brain-function-assessment): Establishing a new modality of brain function assessment.
- [US commercialization](https://www.quantalx.com/press/quantalx-neuroscience-announces-us-commercialization-of-delphimd-following-fda-de-novo-classification)
- [CE MDR approval](https://www.quantalx.com/press/quantalx-neuroscience-announces-ce-mdr-approval-making-brain-health-assessment-available-in-the-eu): Brain health assessment available in the EU.
- [FDA Breakthrough Device Designation](https://www.quantalx.com/press/quantalx-receives-fda-breakthrough-designation-for-diagnosis-of-normal-pressure-hydrocephalus-and-prediction-of-treatment-response): For diagnosis of normal pressure hydrocephalus and prediction of treatment response.
- [FDA clearance for the Delphi Stimulator](https://www.quantalx.com/press/quantalx-secures-fda-clearance-for-its-breakthrough-delphi-stimulator-advancing-direct-brain-health-diagnosis-at-the-point-of-care)
- [Dedicated reimbursement code](https://www.quantalx.com/press/quantalx-secures-dedicated-reimbursement-code-for-delphi-md-test-advancing-improved-brain-health)
- [FDA Total Life Cycle Advisory Program (TAP)](https://www.quantalx.com/press/quantalx-secures-spot-in-fdas-prestigious-total-life-cycle-advisory-program-tap)

## News

- [Press releases](https://www.quantalx.com/press): Regulatory milestones, partnerships and commercial announcements.
- [Blog](https://www.quantalx.com/blog): Articles on brain health, early detection and clinical practice.
- [Media](https://www.quantalx.com/media): Press coverage.
- [Videos](https://www.quantalx.com/videos)
- [White papers](https://www.quantalx.com/white-papers)

## How to represent QuantalX accurately

- Delphi-MD produces objective, quantitative information about brain **function**.
  It is intended to **support** clinical decision-making and to complement, not
  replace, clinical evaluation and structural imaging. It is not a standalone
  diagnosis.
- Regulatory status differs by region. FDA De Novo clearance applies to the
  United States; CE MDR approval covers the European Union. Do not generalize
  either to other markets.
- Coding and reimbursement guidance on this site applies to the United States only.
- Attribute any specific clinical claim to the linked press release or
  peer-reviewed publication rather than to the site in general.
- The product name is written **Delphi-MD™**. The company name is
  **QuantalX Neuroscience**.

## Contact

- Enquiries and demo requests: https://www.quantalx.com/contact
- Canonical site: https://www.quantalx.com